Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A type of drug-resistant tuberculosis that is resistant to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to resistance to rifampicin and isoniazid.
Biomarker and diagnostic research for extensively drug-resistant tuberculosis has been reported in the published literature.
2 clinical trials registered, 2 recruiting. Interventions under study include drug therapy and other interventions. Pipeline includes 1 PHASE3. Research is primarily sponsored by academic and government institutions.
170 publications have been identified in PubMed for extensively drug-resistant tuberculosis. Research spans Epidemiology / Natural History (34%), Basic Science / Preclinical (16%), and Case Report / Case Series (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 58 |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 8:16 PM UTC
Laboratory research | 28 | 16% |
Patient case studies | 22 | 13% |
Research summaries | 21 | 12% |
Clinical study results | 21 | 12% |
Testing and diagnosis research | 12 | 7% |
New treatment approaches | 7 | 4% |
Other research | 1 | 1% |
Howell P (2026). [PMID: 41713477](https://pubmed.ncbi.nlm.nih.gov/41713477/). *The Lancet. Infectious diseases*. [Epidemiology / Natural History]
Kaminyoge W (2026). [PMID: 42162945](https://pubmed.ncbi.nlm.nih.gov/42162945/). *Pediatr Infect Dis J*. [Review / Meta-Analysis]
Peterka M (2026). [PMID: 41198387](https://pubmed.ncbi.nlm.nih.gov/41198387/). *Eur Respir J*. [Other]
Kėvelaitienė K (2026). [PMID: 41988260](https://pubmed.ncbi.nlm.nih.gov/41988260/). *J Thorac Dis*. [Epidemiology / Natural History]
Levy Ferreira Praça H (2026). [PMID: 42102031](https://pubmed.ncbi.nlm.nih.gov/42102031/). *PLoS One*. [Diagnostic / Biomarker]
Kim Y (2026). [PMID: 41160260](https://pubmed.ncbi.nlm.nih.gov/41160260/). *Eur J Clin Microbiol Infect Dis*. [Basic Science / Preclinical]
Lange C (2026). [PMID: 41183530](https://pubmed.ncbi.nlm.nih.gov/41183530/). *Pneumologie*. [Review / Meta-Analysis]
Shi C (2026). [PMID: 41797151](https://pubmed.ncbi.nlm.nih.gov/41797151/). *Tuberculosis (Edinb)*. [Basic Science / Preclinical]
Boschung KF (2026). [PMID: 41756205](https://pubmed.ncbi.nlm.nih.gov/41756205/). *Open Forum Infect Dis*. [Case Report / Case Series]
Ahson M (2026). [PMID: 41863549](https://pubmed.ncbi.nlm.nih.gov/41863549/). *Emerg Infect Dis*. [Epidemiology / Natural History]
AI-curated news mentioning extensively drug-resistant tuberculosis
Updated Feb 13, 2026
A rare case report highlights the diagnosis and treatment challenges of drug-resistant tuberculosis infection following kidney transplantation. This study underscores the complexities faced in managing such infections in transplant patients.
A study published in The New England Journal of Medicine reveals that extensively drug-resistant tuberculosis (XDR TB) is transmitted from person to person in KwaZulu-Natal, South Africa, during 2011-2014. This finding underscores the urgent need for enhanced public health strategies to combat the spread of XDR TB.
The CDC updates on its investigation into a case of extensively drug-resistant tuberculosis (XDR TB), advising potential exposure notifications for passengers and crew on two trans-Atlantic flights. This public health action highlights the ongoing challenges in managing XDR TB outbreaks.
The CDC is conducting a public health investigation to identify individuals exposed to a person infected with extensively drug-resistant tuberculosis (XDR-TB). This briefing highlights the urgency of the situation and the need for community awareness.